Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
暂无分享,去创建一个
Rakesh K. Jain | Mehra Golshan | Matija Snuderl | Marek Ancukiewicz | Eric P. Winer | William T. Barry | Saloni R. Jain | Steven J. Isakoff | E. Winer | R. Jain | W. Barry | Y. Boucher | M. Snuderl | S. Goel | J. Brock | S. Isakoff | M. Ancukiewicz | E. Yeh | S. Tolaney | D. Duda | M. Golshan | I. Krop | John D. Martin | Ian E. Krop | Shom Goel | Yves Boucher | Dan G. Duda | Giorgio Seano | Jane Brock | G. Seano | Sara M. Tolaney | Eren D. Yeh | Johanna Lahdenrata | Johanna Lahdenrata | D. Duda
[1] Pamela F. Jones,et al. A Rac/Cdc42 exchange factor complex promotes formation of lateral filopodia and blood vessel lumen morphogenesis , 2015, Nature Communications.
[2] J. Meyerhardt,et al. Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer , 2012, PloS one.
[3] Christos Hatzis,et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Tracy T Batchelor,et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. , 2012, Cancer research.
[5] Rakesh K. Jain,et al. Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.
[6] G. Sledge. Anti-vascular endothelial growth factor therapy in breast cancer: game over? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Lei Xu,et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.
[8] R. Jain,et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy , 2012, Proceedings of the National Academy of Sciences.
[9] R. Jain,et al. Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases. , 2015, Journal of the National Cancer Institute.
[10] F. André,et al. Bevacizumab: the phoenix of breast oncology? , 2015, The Lancet. Oncology.
[11] Hein Putter,et al. Tumor–stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients , 2011, Breast Cancer Research and Treatment.
[12] G. Bergers,et al. Tumor angiogenesis, from foe to friend , 2015, Science.
[13] V. Goh,et al. Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy , 2013, British Journal of Cancer.
[14] R K Jain,et al. Interstitial hypertension in human breast and colorectal tumors. , 1992, Cancer research.
[15] A. Karsan,et al. A novel population of local pericyte precursor cells in tumor stroma that require Notch signaling for differentiation. , 2015, Microvascular research.
[16] R K Jain,et al. Interstitial hypertension in superficial metastatic melanomas in humans. , 1991, Cancer research.
[17] Rakesh K. Jain,et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels , 2013, Nature Communications.
[18] G. Hortobagyi,et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Ioannidis,et al. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. , 2005, Journal of the National Cancer Institute.
[20] M. Parmar,et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. , 2013, The Lancet. Oncology.
[21] Frederik De Smet,et al. Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization , 2009, Cell.
[22] Jianhua Huang,et al. A Role for VEGF as a Negative Regulator of Pericyte Function and Vessel Maturation , 2008, Nature.
[23] A. Harris,et al. Hypoxia-Inducible Factor 1α Expression as an Intrinsic Marker of Hypoxia , 2004, Clinical Cancer Research.
[24] Triantafyllos Stylianopoulos,et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors , 2012, Proceedings of the National Academy of Sciences.
[25] P. Carmeliet,et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. , 2012, The Lancet. Oncology.
[26] R. DePinho,et al. Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure. , 2014, Cancer cell.
[27] Quing Zhu,et al. Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteria , 2014, Breast Cancer Research.
[28] D. Berry,et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] O. Gevaert,et al. Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial , 2015, British Journal of Cancer.
[30] Anna L. Brown,et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Marek Ancukiewicz,et al. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer , 2015, Proceedings of the National Academy of Sciences.
[32] Jeffrey W. Clark,et al. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. , 2010, The oncologist.
[33] Ricky T. Tong,et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.
[34] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[35] Z. Shao,et al. Clinical and Pathological Response to Neoadjuvant Chemotherapy Based on Primary Tumor Reduction is Correlated to Survival in Hormone Receptor-Positive but not Hormone Receptor-Negative Locally Advanced Breast Cancer , 2014, Annals of Surgical Oncology.
[36] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[38] Ricky T. Tong,et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] James A Young,et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. , 2012, The New England journal of medicine.
[40] Tracy T Batchelor,et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.
[41] D. Sahani,et al. Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study , 2013, Clinical Cancer Research.
[42] M J Bissell,et al. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. , 1996, Physiological reviews.
[43] R. Jain,et al. Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948) , 2012, PloS one.
[44] J. García-Foncillas,et al. Dynamic contrast-enhanced MRI versus 18F-misonidazol-PET/CT to predict pathologic response in bevacizumab-based neoadjuvant therapy in breast cancer. , 2012 .
[45] A. Wree,et al. Lack of Correlation between Expression of HIF-1α Protein and Oxygenation Status in Identical Tissue Areas of Squamous Cell Carcinomas of the Uterine Cervix , 2004, Cancer Research.
[46] Markus Rudin,et al. Longitudinal and multimodal in vivo imaging of tumor hypoxia and its downstream molecular events , 2009, Proceedings of the National Academy of Sciences.
[47] P. Carmeliet,et al. Markers of response for the antiangiogenic agent bevacizumab. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] Charles Swanton,et al. Clinical management of breast cancer heterogeneity , 2015, Nature Reviews Clinical Oncology.
[49] R. Jain,et al. Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. , 2013, Journal of the National Cancer Institute.
[50] Tanja Fehm,et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. , 2012, The New England journal of medicine.
[51] A. Hutcheon,et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. , 2003, Breast.
[52] C. Caldas,et al. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. , 2015, The Lancet. Oncology.
[53] A. Yoshizawa,et al. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer , 2012, Angiogenesis.
[54] Ricky T. Tong,et al. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. , 2007, Cancer research.
[55] P. Wen,et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. , 2009, Cancer research.
[56] B. Rosen,et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation , 2013, Proceedings of the National Academy of Sciences.
[57] R. Jain,et al. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. , 2014, Cancer cell.